BTK-IN-15(compound 42)是一种具有良好口服活性的新型布鲁顿酪氨酸激酶(BTK)抑制剂,可抑制 BTK(IC50 为 0.7 nM),并具有良好的激酶选择性和抗肿瘤活性,能诱导癌细胞凋亡(apoptosis)。
产品编号: MS-W72579 CAS No.: 2820426-92-2 分子式: C28H24FN5O2 分子量: 481.52
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

BTK-IN-15(compound 42)是一种具有良好口服活性的新型布鲁顿酪氨酸激酶(BTK)抑制剂,可抑制 BTK(IC50 为 0.7 nM),并具有良好的激酶选择性和抗肿瘤活性,能诱导癌细胞凋亡(apoptosis)。

生物实验数据

生物活性 BTK-IN-15 (compound 42) is a novel Bruton's tyrosine kinase (BTK) inhibitor with good oral activity that inhibits BTK with an IC50 of 0.7 nM and exhibits good kinase selectivity and antitumor activity, inducing cancer cell apoptosis.
IC50 & Target

IC50: 0.7 nM (BTK)

体外研究
(In Vitro)

BTK inhibition is an effective approach against B-cell malignancies.
BTK-IN-15 (compound 42) demonstrates inhibitory against TMD8 with an IC50 value of 2.6 nM.
BTK-IN-15 (1 μM; 1 h) displays significant selectivity to BTK over EGFR kinase with 0.05% and 44% of the control, respectively.
BTK-IN-15 (0-1 mM; 72 h) exerts potent anti-proliferative activity against a human mantle cell lymphoma cell line (REC-1) with an IC50 value of 1.7 nM.
BTK-IN-15 (0-1 mM; 2 h) inhibits BTK auto-phosphorylation with an IC50 value of 1.49 nM.
BTK-IN-15 (0-100 nM; 48 h) arrests cell cycle at G1 phase and (0-1 mM; 72 h) induces apoptosis in TMD8.
BTK-IN-15 shows low hERG channel activity (IC50=4.38 μM), indicating low cardiotoxicity.

Western Blot Analysis

Cell Line: B-cell lymphoma (DLBCL) TMD8 cancer cells
Concentration: 0, 0.15, 0.46, 1.37, 4.12, 12.35, 37.04, 111, 333, 1000 nM
Incubation Time: 2 hours
Result: Inhibited BTK auto-phosphorylation at the Tyr223 site with an IC50 value of 1.49 nM.

Cell Cycle Analysis

Cell Line: B-cell lymphoma (DLBCL) TMD8 cancer cells
Concentration: 0, 10, 100 nM
Incubation Time: 48 hours
Result: Arrested cell cycle progression at G1 phase in a dose-dependent manner, the percentage of cells in the G0/G1 phase increased from 33.0 to 63.0% with a dose range of 1-100 nM.

Apoptosis Analysis

Cell Line: B-cell lymphoma (DLBCL) TMD8 cancer cells
Concentration: 0, 10, 100, 1000 nM
Incubation Time: 72 hours
Result: Induced apoptosis of TMD8 cells in a weakly triggered concentration-dependent manner, with the apoptosis cell values of 19% (10 nM), 25.2% (100 nM), and 31.4% (1000 nM), respectively.
体内研究
(In Vivo)

BTK-IN-15 (compound 42) (12.5-50 mg/kg; p.o.; twice daily; 21 d) inhibits tumor growth (TGI = 104%) at a dosage of 50 mg/kg in mice.
BTK-IN-15 (300, 400, 500 mg/kg; p.o.; twice daily; 14 d) has biological safety and displays no affect against body weight in mice compared with control.
BTK-IN-15 (10 mg/kg; p.o.) shows a high oral bioavailability of 40.98% in mice.
Pharmacokinetics of BTK-IN-15 in Mice

Route Dose (mg/kg) Tmax (h) Cmax (ng/mL) AUC(0-t) (h•ng/mL) AUC(0-∞) (h•ng/mL) T1/2 (h) Vz (L/kg) CL (L/h/kg) F (%)
i.v. 2 0.03 2245.39 1471.35 718.33 0.67 2.79 2.87 40.98
p.o. 10 0.39 1441.59 718.33 1472.06 0.59

Animal Model: Female CB-17 SCID nude mice with TMD8 xenograft model
Dosage: 12.5 mg/kg, 25 mg/kg, and 50 mg/kg
Administration: Oral gavage; twice daily; 21 days
Result: Inhibited tumor growth at a dosage of 50 mg/kg and reduced tumor volume after 21 days with a TGI of 104%.
Reduced the content of white blood cells, lymphocytes and monocytes, while showed no effect on red blood cell and platelets.
Animal Model: ICR mice (acclimation for 5 days, 18-20 g)
Dosage: 300, 400, 500 mg/kg
Administration: Oral gavage; 14 days
Result: Demonstrated no affect against body weight in mice compared with control.

化学信息

分子量 481.52
分子式 C28H24FN5O2
CAS No. 2820426-92-2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础